{"id":"https://openalex.org/W2246031346","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.10565","title":"Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors.","display_name":"Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2246031346","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.10565","mag":"2246031346"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.10565","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.10565","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.10565","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090794974","display_name":"Yongli Liu","orcid":"https://orcid.org/0009-0006-9302-5021","observed_orcids":["https://orcid.org/0009-0006-9302-5021"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y. Liu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062010101","display_name":"Mark D. Starr","orcid":"https://orcid.org/0009-0003-9664-6235","observed_orcids":["https://orcid.org/0009-0003-9664-6235"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Starr","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084337375","display_name":"Herbert Pang","orcid":"https://orcid.org/0000-0002-7896-6716","observed_orcids":["https://orcid.org/0000-0002-7896-6716"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Pang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020491326","display_name":"Jennifer E. Marcello","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Marcello","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110265946","display_name":"B. R. Leigh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. R. Leigh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005320639","display_name":"C. P. Theuer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. P. Theuer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046311492","display_name":"Herbert I. Hurwitz","orcid":"https://orcid.org/0000-0003-3242-9197","observed_orcids":["https://orcid.org/0000-0003-3242-9197"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Hurwitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5073511088","display_name":"A. Nixon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. B. Nixon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"10565","last_page":"10565"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11469","display_name":"Lymphatic System and Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/endoglin","display_name":"CD105","score":0.9909999966621399},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.8989999890327454},{"id":"https://openalex.org/keywords/angiogenic-biomarkers","display_name":"angiogenic biomarkers","score":0.9750000238418579},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.7749999761581421},{"id":"https://openalex.org/keywords/vegf-c","display_name":"VEGF-C","score":0.7580000162124634},{"id":"https://openalex.org/keywords/vegf-d","display_name":"VEGF-D","score":0.9980000257492065},{"id":"https://openalex.org/keywords/igfbp-3","display_name":"IGFBP-3","score":0.9750000238418579},{"id":"https://openalex.org/keywords/platelet-derived-growth-factor","display_name":"platelet-derived growth factor","score":0.7480000257492065},{"id":"https://openalex.org/keywords/placental-growth-factor","display_name":"placental growth factor","score":0.8320000171661377},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.6610000133514404},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.7390000224113464},{"id":"https://openalex.org/keywords/multiplex-elisa","display_name":"multiplex ELISA","score":0.7760000228881836}],"concepts":[{"id":"https://openalex.org/C6061869","wikidata":"https://www.wikidata.org/wiki/Q18250377","display_name":"Endoglin","level":4,"score":0.8569016456604004},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8036675453186035},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.6939024925231934},{"id":"https://openalex.org/C2781188995","wikidata":"https://www.wikidata.org/wiki/Q6934982","display_name":"Multiplex","level":2,"score":0.5916953682899475},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5878615379333496},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.518374502658844},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48520544171333313},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.44027018547058105},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38493993878364563},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3712441623210907},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22770604491233826},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.12021461129188538},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0914061963558197},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08731180429458618},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.0},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.10565","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.10565","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.10565","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7020945910","https://openalex.org/W1967023901","https://openalex.org/W2504884892","https://openalex.org/W2601269790","https://openalex.org/W2589551348","https://openalex.org/W2890986664","https://openalex.org/W2402838931","https://openalex.org/W3080323338","https://openalex.org/W2414844068","https://openalex.org/W2023949193"],"abstract_inverted_index":{"10565":[0],"Background:":[1],"CD105":[2],"(endoglin)":[3],"is":[4,12,20,187,210],"an":[5,21,32],"important":[6],"mediator":[7],"of":[8,54,99,124,192,195,214,217,225,256],"tumor":[9,83],"angiogenesis":[10,218],"that":[11,134,207,219],"upregulated":[13],"by":[14],"hypoxia":[15],"and":[16,86,96,160,182,252,263],"VEGF":[17,261],"inhibitors.":[18],"TRC105":[19,107,196,208,242,257],"anti-CD105":[22],"monoclonal":[23],"antibody":[24],"currently":[25],"being":[26],"evaluated":[27],"in":[28,200,258],"clinical":[29,202],"trials":[30],"as":[31,244,246],"anti-angiogenic":[33],"cancer":[34,76,266],"therapy.":[35],"Methods:":[36],"In":[37],"this":[38],"first-in-human":[39],"phase":[40,250,253],"I":[41],"study,":[42],"pts":[43,104,238,247],"with":[44,51,106,126,146,212,260],"advanced,":[45],"incurable":[46],"solid":[47],"tumors":[48],"were":[49,66,88,111,120,138,172],"treated":[50,105,239,248],"escalating":[52],"doses":[53,243],"TRC105,":[55],"iv":[56],"every":[57],"2":[58],"wks,":[59],"until":[60],"disease":[61,226],"progression.":[62,227],"Serial":[63],"plasma":[64],"samples":[65],"analyzed":[67],"via":[68],"a":[69],"novel":[70],"multiplex":[71],"ELISA":[72],"platform":[73],"optimized":[74],"for":[75,113,122,174,237],"patients.":[77],"39":[78],"candidate":[79],"biomarkers":[80,199],"related":[81],"to":[82],"growth,":[84],"angiogenesis,":[85],"inflammation":[87],"assayed":[89],"at":[90,97,108,141,222,240],"baseline":[91],"(BL),":[92],"after":[93],"1":[94,169],"month,":[95],"end":[98],"study":[100],"(EOS).":[101],"Results:":[102],"19":[103],"0.01-1":[109],"mg/kg":[110],"evaluable":[112],"biomarker":[114],"analysis.":[115],"Spearman\u2019s":[116],"rank":[117,131],"correlation":[118],"coefficients":[119],"calculated":[121],"pairs":[123],"analytes":[125,137],"known":[127],"interactions.":[128],"Wilcoxon":[129],"signed":[130],"tests":[132],"indicated":[133],"the":[135,168,175,188,193,201,223],"following":[136,176],"significantly":[139],"down-regulated":[140],"one":[142],"month":[143,170],"when":[144],"compared":[145],"baseline:":[147],"IGFBP-3":[148,183],"(p=0.001),":[149],"VEGF-C":[150,178],"(p=0.002),":[151],"VEGF-D":[152,180],"(p=0.003),":[153],"FGFb":[154],"(p=0.008),":[155],"PDGF-AA":[156],"(p=0.011),":[157],"PDGF-BB":[158],"(p=0.039),":[159],"PIGF":[161],"(p=0.045).":[162],"By":[163],"EOS,":[164],"significant":[165],"increases":[166],"from":[167],"nadir":[171],"observed":[173],"analytes:":[177],"(p=0.027),":[179],"(p=0.034),":[181],"(p=0.043).":[184],"Conclusions:":[185],"This":[186],"first":[189],"systematic":[190],"investigation":[191],"effect(s)":[194],"on":[197,229,249],"angiogenic":[198],"setting.":[203],"Multiplex":[204],"analyses":[205,234],"indicate":[206],"therapy":[209],"associated":[211],"down-regulation":[213],"key":[215],"modulators":[216],"later":[220],"increase":[221],"time":[224],"Based":[228],"these":[230],"preliminary":[231],"findings,":[232],"additional":[233],"are":[235],"planned":[236],"higher":[241],"well":[245],"Ib":[251],"II":[254],"studies":[255],"combination":[259],"inhibitors":[262],"other":[264],"standard-of-care":[265],"therapies.":[267]},"counts_by_year":[{"year":2014,"cited_by_count":2}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}